TABLE 3.
Effect of lamivudine on buprenorphine and buprenorphine metabolites in plasma
| Pharmacokinetic parameter | Pre-lamivudine | Post-lamivudine | p value |
|---|---|---|---|
| Buprenorphine | |||
| AUC0–24 (ng h/ml) | 41.3 (5.5) | 45.2 (6.9) | 0.19 |
| Cl/F (L/h) | 435 (65) | 409 (66) | 0.30 |
| Cmax (ng/ml) | 5.60 (0.90) | 5.72 (0.91) | 0.88 |
| Tmax (h) | 1.0 (1.0–2.0) | 1.0 (0.5–1.5) | NS |
| Cmin (ng/ml) | 1.07 (0.17) | 1.11 (0.22) | 0.67 |
| Norbuprenorphine | |||
| AUC0–24 (ng h/ml) | 45.0 (7.5) | 50.3 (8.2) | 0.13 |
| Cl/F (L/h) | 415 (61) | 371 (57) | 0.13 |
| Cmax (ng/ml) | 3.53 (0.68) | 3.75 (0.59) | 0.93 |
| Tmax (h) | 2.0 (1.5–2.0) | 2.0 (0.5–4.0) | NS |
| Cmin (ng/ml) | 1.41 (0.20) | 1.53 (0.32) | 0.44 |
| Buprenorphine-3-glucuronide | |||
| AUC0–24 (ng h/ml) | 26.8 (9.4) | 33.0 (12.4) | 0.06 |
| Cl/F (L/h) | 1499 (515) | 1371 (515) | 0.13 |
| Cmax (ng/ml) | 7.45 (2.76) | 7.38 (2.27) | 0.59 |
| Tmax (h) | 1.0 (1.0–2.0) | 0.5 (0.5–1.5) | NS |
| Cmin (ng/ml) | 0.51 (0.19) | 0.91 (0.42) | 0.44 |
| Norbuprenorphine-3-glucuronide | |||
| AUC0–24 (ngh/ml) | 177 (45) | 205 (48) | 0.02 |
| Cl/F (L/h) | 127 (27) | 104 (20) | 0.13 |
| Cmax (ng/ml) | 14.8 (4.5) | 18.8 (4.5) | 0.04 |
| Tmax (h) | 2.0 (1.5–4.0) | 2.0 (0.5–4) | NS |
| Cmin (ng/ml) | 4.4 (0.8) | 5.5 (1.5) | 0.17 |